Total Payments
$71,539
2024 Payments
$40,330
Companies
14
Transactions
63
Medicare Patients
979
Medicare Billing
$83,931
Payment Breakdown by Category
Consulting$64,541 (90.2%)
Research$4,470 (6.2%)
Travel$1,086 (1.5%)
Food & Beverage$812.17 (1.1%)
Other$600.00 (0.8%)
Education$30.27 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $64,541 | 40 | 90.2% |
| Unspecified | $4,470 | 3 | 6.2% |
| Travel and Lodging | $1,086 | 4 | 1.5% |
| Food and Beverage | $812.17 | 11 | 1.1% |
| Honoraria | $400.00 | 2 | 0.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $200.00 | 1 | 0.3% |
| Education | $30.27 | 2 | 0.0% |
Payments by Type
General
$67,069
60 transactions
Research
$4,470
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $25,093 | 19 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $9,112 | 15 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $7,663 | 6 | $0 (2024) |
| Daiichi Sankyo Inc. | $6,999 | 4 | $0 (2024) |
| Amgen Inc. | $6,000 | 3 | $0 (2024) |
| BeiGene USA, Inc. | $4,550 | 2 | $0 (2023) |
| PFIZER INC. | $4,470 | 3 | $0 (2024) |
| Janssen Biotech, Inc. | $2,207 | 3 | $0 (2023) |
| Astellas Pharma Global Development | $2,172 | 1 | $0 (2024) |
| Genentech, Inc. | $1,578 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $40,330 | 33 | AstraZeneca Pharmaceuticals LP ($15,936) |
| 2023 | $25,524 | 20 | AstraZeneca Pharmaceuticals LP ($7,770) |
| 2022 | $5,665 | 9 | Janssen Scientific Affairs, LLC ($3,788) |
| 2020 | $19.42 | 1 | E.R. Squibb & Sons, L.L.C. ($19.42) |
All Payment Transactions
63 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $101.29 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Astellas Pharma Global Development | Vyloy (Drug) | Consulting Fee | Cash or cash equivalent | $2,172.00 | General |
| Category: Oncology | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,010.00 | General |
| 11/12/2024 | PFIZER INC. | IBRANCE (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: IBRANCE CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 11/06/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $3,885.00 | General |
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,497.50 | General |
| 10/22/2024 | Janssen Scientific Affairs, LLC | TECVAYLI (Biological) | Consulting Fee | Cash or cash equivalent | $1,150.00 | General |
| Category: Oncology | ||||||
| 10/19/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| 10/07/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | In-kind items and services | $134.48 | General |
| Category: Oncology | ||||||
| 09/19/2024 | AstraZeneca Pharmaceuticals LP | LUMOXITI (Biological) | Consulting Fee | Cash or cash equivalent | $1,942.50 | General |
| Category: Oncology | ||||||
| 09/06/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| 09/03/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,942.50 | General |
| 07/15/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,710.00 | General |
| 06/26/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,665.00 | General |
| 06/24/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $555.00 | General |
| 05/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 05/16/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,710.00 | General |
| 05/16/2024 | PFIZER INC. | IBRANCE (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: IBRANCE CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 05/16/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $182.00 | General |
| 05/16/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $130.00 | General |
| 05/16/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $52.00 | General |
| 05/07/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,387.50 | General |
| 04/26/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $321.45 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| IBRANCE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,470 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 188 | 327 | $77,603 | $15,831 |
| 2022 | 8 | 213 | 381 | $94,251 | $21,301 |
| 2021 | 8 | 214 | 349 | $74,067 | $19,960 |
| 2020 | 12 | 364 | 606 | $106,033 | $26,839 |
Total Patients
979
Total Services
1,663
Medicare Billing
$83,931
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 47 | 95 | $47,310 | $9,890 | 20.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 59 | 80 | $26,800 | $4,909 | 18.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 33 | 66 | $1,386 | $529.29 | 38.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 24 | 47 | $1,422 | $334.84 | 23.6% |
| 82565 | Blood creatinine level | Office | 2023 | 12 | 19 | $380.00 | $95.38 | 25.1% |
| 82947 | Blood glucose (sugar) level | Office | 2023 | 13 | 20 | $305.00 | $73.15 | 24.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 31 | 87 | $40,542 | $9,055 | 22.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 59 | 92 | $29,164 | $5,881 | 20.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 16 | 37 | $12,062 | $2,970 | 24.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 17 | 17 | $7,293 | $1,778 | 24.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 12 | 13 | $2,015 | $1,004 | 49.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 28 | 49 | $1,482 | $353.18 | 23.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 34 | 67 | $1,403 | $190.02 | 13.5% |
| 82947 | Blood glucose (sugar) level | Office | 2022 | 16 | 19 | $289.75 | $69.90 | 24.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 37 | 79 | $28,124 | $8,648 | 30.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 64 | 102 | $25,704 | $6,215 | 24.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 15 | 28 | $9,296 | $2,188 | 23.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 11 | 11 | $4,840 | $1,063 | 22.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 11 | 15 | $1,860 | $946.80 | 50.9% |
| 99451 | Telephone or internet assessment and management service provided by consultative physician with written report, 5 minutes or more of medical consultative discussion and review | Facility | 2021 | 16 | 16 | $1,888 | $426.90 | 22.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 26 | 43 | $1,258 | $310.80 | 24.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 34 | 55 | $1,097 | $160.50 | 14.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 99 | 197 | $46,886 | $10,861 | 23.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 40 | 51 | $9,027 | $3,124 | 34.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 22 | 22 | $9,086 | $2,347 | 25.8% |
About Yan Ji, M.D, PH.D
Yan Ji, M.D, PH.D is a Hematology & Oncology healthcare provider based in Saint Paul, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/23/2010. The National Provider Identifier (NPI) number assigned to this provider is 1225355829.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Yan Ji, M.D, PH.D has received a total of $71,539 in payments from pharmaceutical and medical device companies, with $40,330 received in 2024. These payments were reported across 63 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($64,541).
As a Medicare-enrolled provider, Ji has provided services to 979 Medicare beneficiaries, totaling 1,663 services with total Medicare billing of $83,931. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Saint Paul, MN
- Active Since 04/23/2010
- Last Updated 03/18/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1225355829
Products in Payments
- IMBRUVICA (Drug) $4,665
- IBRANCE (Drug) $4,470
- ENHERTU (Biological) $4,163
- TECVAYLI (Biological) $2,500
- Vyloy (Drug) $2,172
- BRUKINSA (Drug) $1,950
- LUMOXITI (Biological) $1,943
- TAGRISSO (Drug) $1,943
- Venclexta (Biological) $1,515
- CALQUENCE (Drug) $1,388
- IMFINZI (Biological) $1,059
- CARVYKTI (Drug) $840.00
- RYBREVANT (Drug) $757.50
- LYNPARZA (Drug) $101.29
- Revlimid (Drug) $19.42
- ERLEADA (Drug) $16.58
- LYNPARZA (Biological) $10.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Saint Paul
Kurt Demel, Md, MD
Hematology & Oncology — Payments: $22,510
Hematology & Oncology $22,510
Daniel Anderson, Md, MD
Hematology & Oncology — Payments: $13,524
Hematology & Oncology $13,524
Christine Ding, M.d, M.D
Hematology & Oncology — Payments: $1,285
Hematology & Oncology $1,285
Dr. Sara Torgerson, D.o, D.O
Hematology & Oncology — Payments: $988.23
Hematology & Oncology $988.23
Timothy Toonen, M.d, M.D
Hematology & Oncology — Payments: $595.24
Hematology & Oncology $595.24
Dr. Bhaskar Kolla, M.d, M.D
Hematology & Oncology — Payments: $125.00
Hematology & Oncology $125.00